Product Information
Registration Status: ActiveEXELON CAPSULE 4.5mg is approved to be sold in Singapore with effective from 1998-09-24. It is marketed by NOVARTIS (SINGAPORE) PTE LTD, with the registration number of SIN10037P.
This product contains Rivastigmine 4.5mg in the form of CAPSULE. It is approved for ORAL use.
This product is manufactured by NOVARTIS FARMACEUTICA SA (bottle in SPAIN.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Indication
For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
Mechanism of Action
Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues.
Clearance
* renal cl=2.1-2.8 L/hr
Active Ingredient/Synonyms
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate | m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate | Rivastigmine |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.